- Datum07.04.2025
- Uhrzeit15:00 - 16:00 Uhr
- Veranstalter
LYNX
Achim Mautz
Moderator
Pyxis Oncology Aktie
Verkaufen
Kaufen
Pyxis Oncology Chart
Pyxis Oncology Realtime-Kurs
| Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| Nasdaq | VK | |||||
| Nasdaq Basic | VK | |||||
| Cboe BZX | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
-0,98 %
Intraday
-14,01 %
1 Woche
-22,09 %
1 Monat
-41,57 %
Seit Jahresbeginn
-83,31 %
1 Jahr
-73,27 %
3 Jahre
Wikifolio
Passender Service zu Pyxis Oncology
Webinar zu Pyxis Oncology
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)0,860-5,740
- Jahrestief / Hoch ($)0,860-1,820
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Pyxis Oncology
Keine Dividenden verfügbar
Termine von Pyxis Oncology
Keine aktuellen Termine
Beschreibung
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
